Ipilimumab vs Midazolam
Ipilimumab vs Midazolam: Overview
This comparison examines the pharmacological differences between Ipilimumab and Midazolam.
Mechanism of Action
Ipilimumab: Fully human anti-CTLA-4 IgG1 monoclonal antibody that blocks CTLA-4 inhibitory signaling.
Midazolam: Ultra-short-acting benzodiazepine GABA-A receptor positive allosteric modulator.
Pharmacokinetics
Half-life: Ipilimumab — 14.7 days; Midazolam — 1.5-2.5 hours.
Chemical Properties
Molecular Formula: Midazolam — C18H13ClFN3.
Molecular Weight: Midazolam — 325.7670 g/mol.
Type: Ipilimumab — Antibody; Midazolam — Small molecule.